9903.04.68: Section 232 Pharma Exemption for U.S. Products

Key Points

• 9903.04.68 is a Pharmaceuticals 232 heading that carries 0 percent additional duty, so it is an exemption or claim heading, not a duty heading.
• The heading text covers pharmaceutical products with an active pharmaceutical ingredient packaged in dosage form that is a product of the United States.
• The legal authority in the facts is Procl. 11020 (91 FR 18183) and U.S. note 40, with an effective date of July 31, 2026 for Annex III and September 29, 2026 for all companies.
• Using the heading does not remove the regular chapter 1-97 line from the entry; the Chapter 99 line rides alongside it.
• The conditions for claiming it live in U.S. note 40 in the HTSUS, so read the note before you file.

On this page

1. What 9903.04.68 is and what it is not
2. Affected products and scope
3. Rate and effective dates
4. How it appears on an entry and interacts with other duties
5. What importers should do
6. Key references

9903.04.68 is the Chapter 99 heading for pharmaceutical products in dosage form that are a product of the United States, under the Pharmaceuticals 232 program. It matters to any importer of pharmaceuticals, including U.S. goods coming back across the border. The additional duty on this heading is 0 percent. This article reflects the facts as of October 2026.

The links in this article go to the primary documents: the proclamations, Federal Register notices, and official tariff schedule pages themselves. Read the source.

What 9903.04.68 is and what it is not

The official heading text reads: "Pharmaceutical products with an active pharmaceutical ingredient packaged in dosage form that is a product of the United States." It sits in the Pharmaceuticals 232 program, which is built on Procl. 11020 (91 FR 18183) and U.S. note 40 to the relevant HTSUS subchapter. You can search the proclamation's Federal Register citation at federalregister.gov.

The key point is what this heading does not do. It does not impose a tariff. It is an exemption, exception, or claim heading inside a program that does impose duties elsewhere. Filing under it tells CBP that the goods fall in a category the program treats at 0 percent additional duty.

If you are comparing it with neighboring headings, those articles cover their own scopes: 9903.04.67 for generic pharmaceuticals at 0%, 9903.04.65 for the onshoring and MFN 0% heading, and 9903.04.62 at 15 percent. Each heading has its own text, so match your goods to the heading wording, not to the program name.

Affected products and scope

What the heading text covers

Three elements appear in the heading text:

• A pharmaceutical product.
• An active pharmaceutical ingredient packaged in dosage form.
• A product of the United States.

The origin element is the one that sets this heading apart. The text names the United States as the product's origin. It does not name any other country, and it does not carry an onshoring-plan condition in its wording.

What the facts do not settle

The facts available here do not list the HTS subheadings that pair with this heading, and they do not define how "product of the United States" is determined for a given shipment. Confirm both in the current HTSUS, in U.S. note 40, or with your broker. Do not infer coverage from the heading name alone.

Rate and effective dates

The additional duty under 9903.04.68 is 0 percent. The facts give the effective timing as follows: July 31, 2026 for Annex III, and September 29, 2026 for all companies. Both dates are tied to the authority line for this heading, Procl. 11020 (91 FR 18183) and U.S. note 40.

Read together, that means the 0 percent treatment applies from July 31, 2026 for goods under Annex III and from September 29, 2026 for all companies. The facts do not explain how Annex III is composed, so check the annex text and the note for which products and parties fall under each date.

The 0 percent figure is the additional duty under this heading only. It says nothing about the ordinary column 1 duty on the underlying line, which stays whatever the HTSUS says for that subheading.

How it appears on an entry and interacts with other duties

A Chapter 99 code does not replace the product's regular classification. The filing pairs two lines:

• The regular chapter 1-97 HTS line that classifies the pharmaceutical product, with its usual duty.
• The Chapter 99 line, here 9903.04.68, that records the program treatment at 0 percent additional duty.

Choosing among sibling headings

The Pharmaceuticals 232 program has several headings with different texts and rates. For an entry, the heading you cite should be the one whose text your goods actually meet. The program's duty-bearing headings are covered separately, for example 9903.04.60 at 100 percent and 9903.04.64 at 20 percent for onshoring plan goods. Those articles describe what the facts say for those codes.

Other tariff programs

The facts do not state how this heading interacts with other tariff programs such as Section 301 or reciprocal duties. Confirm stacking treatment in the current HTSUS and with your broker. For broader context, see the 2026 tariff code overview.

Plan and MFN-pricing mechanics

Some Pharmaceuticals 232 headings depend on onshoring plans or MFN pricing arrangements. This heading's text does not mention either. For any plan or pricing mechanics that may still affect your shipment, go to U.S. note 40 in the HTSUS rather than relying on a summary.

What importers should do

• Read the heading text and U.S. note 40 in the HTSUS, and document why each product is a pharmaceutical in dosage form and a product of the United States.
• Check whether your goods fall under Annex III (July 31, 2026) or the all-companies date (September 29, 2026), and match the entry date to the right window.
• Have your broker transmit the regular chapter 1-97 line together with 9903.04.68, and review sibling headings if any product does not meet the exact text.
• If a shipment was entered under a duty-bearing heading when this one fit, review the options in customs recovery for overpaid duty and watch the deadlines.

Key references

• Federal Register: search for Procl. 11020 (91 FR 18183), the proclamation behind the Pharmaceuticals 232 program.
• Harmonized Tariff Schedule of the United States: the official schedule, including Chapter 99 heading 9903.04.68 and U.S. note 40.
• U.S. Customs and Border Protection: the agency's guidance and CSMS messages on filing Chapter 99 headings.